Nithya Ramnath
Expertise in
9
conditions

Dr. Nithya Ramnath

Oncology
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 
Expertise in
9
conditions
University Of Michigan Medical Center
1500 E Medical Center Dr, 
Ann Arbor, MI 

Overview

Nithya Ramnath is an Oncologist in Ann Arbor, Michigan. Dr. Ramnath is highly rated in 9 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Pleuropulmonary Blastoma, and Lung Adenocarcinoma.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
McLaren Health
  • HMO

Locations

University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI 48109
Other Locations
Regents of the University of Michigan
3621 S State St, Ann Arbor, MI 48108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
Enrollment Status: Terminated
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
Study Phase: Phase 1/Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy
Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drug: Dexamthasone
Study Phase: Phase 1/Phase 2
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug
Study Drug: INC280
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer
A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 08, 2019
Intervention Type: Radiation, Drug
Study Phase: Early Phase 1
View 7 Less Clinical Trials

97 Total Publications

The effect of common medications on the efficacy of immune checkpoint inhibitors.
The effect of common medications on the efficacy of immune checkpoint inhibitors.
Journal: Cancer
Published: August 17, 2025
Similar Doctors
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology

Office

1500 E Medical Center Dr Spc 5912, 
Ann Arbor, MI 
 (0.1 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rashmi Chugh is an Oncologist in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma.

Expertise in
30
conditions
Dr. Scott Schuetze
Oncology
Expertise in
30
conditions
Dr. Scott Schuetze
Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (0.2 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Schuetze is an Oncologist in Ann Arbor, Michigan. Dr. Schuetze is highly rated in 30 conditions, according to our data. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

Expertise in
33
conditions
Dr. Francis Worden
Oncology
Expertise in
33
conditions
Dr. Francis Worden
Oncology

Office

1500 E Medical Center Dr Spc 5848, 
Ann Arbor, MI 
 (0.1 miles away)
734-936-7184
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francis Worden is an Oncologist in Ann Arbor, Michigan. Dr. Worden is highly rated in 33 conditions, according to our data. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Frequently Asked Questions about Dr. Nithya Ramnath

How do I make an appointment with Dr. Nithya Ramnath?

You can book an appointment with Dr. Nithya Ramnath by calling their office at 734-647-8902. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nithya Ramnath a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nithya Ramnath is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nithya Ramnath specialize in?

While Dr. Nithya Ramnath is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nithya Ramnath participate in research or clinical trials?

Yes. Dr. Nithya Ramnath has published 97 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Nithya Ramnath's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nithya Ramnath accept my insurance?

Dr. Nithya Ramnath accepts most major insurance plans, including Blue Cross Blue Shield and McLaren Health. We recommend calling the office directly at 734-647-8902 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ramnath's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile